Alentis Therapeutics Appoints Lung Experts Professors Tony Mok and Steven Nathan to its Scientific A

BASEL, Switzerland--(BUSINESS WIRE)--#CLDN1--Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today the appointment of Tony Mok, Professor of Clinical Oncology at the Chinese University of Hong Kong a...

Related Keywords

Hong Kong ,France ,University Of Hong Kong ,Hong Kong General ,Johannesburg ,Gauteng ,South Africa ,Switzerland ,Long Island Jewish Medical Center ,New York ,United States ,Sariette Witte ,Steven Nathan ,Tony Mok ,Los Angeles ,Luigi Manenti ,Thomas Baumert ,Opatrick Wilson ,Sinai Medical Center ,University Of Virginia ,Department Of Clinical Oncology ,Drug Administration ,Stephen College Council ,Therapy Devices Panel ,Program At Inova Fairfax Hospital ,Lung Transplant Program At Inova Fairfax Hospital ,French National Institute Of Health Inserm ,Chinese University Of Hong Kong ,University Of Strasbourg ,Claudin Technology Platform ,Alenti Claudin Technology Platform ,Astrazeneca ,University Of The Witwatersrand ,Li Shu Fan Medical Foundation ,Hong Kong Academy Of Sciences ,Alentis Therapeutics ,Clinical Oncology ,Chinese University ,Scientific Advisory ,Scientific Advisory Board ,Chief Medical Officer ,Medical Director ,Advanced Lung Disease ,Transplant Program ,Inova Fairfax Hospital ,Aurora Tele Oncology ,College Council ,Hong Kong Academy ,New England Journal ,Clarivate Analytics ,Lung Transplant Program ,Cedars Sinai Medical Center ,Respiratory Therapy Devices ,French National Institute ,